On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Hebron University

InstitutionResearch output, impact & collaborations

Hebron University is a institution indexed in ScholarIQ from OpenAlex.

What is known about Hebron University?

ScholarIQrecord summary

Hebron University is a research organisation in Hebron, PS. OpenAlex records 1,773 works and 66,870 citations for it. 1,449 researchers list it as their most recent affiliation.

How many works does Hebron University have?

ScholarIQindexed works

Hebron University has 1,773 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Hebron University have?

ScholarIQcitation count

Hebron University has 66,870 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Hebron University?

ScholarIQresearcher count

Hebron University has 1,449 researchers in the ScholarIQ index.

What is the average h-index at Hebron University?

ScholarIQavg h-index

Hebron University has an average h-index of 76.6 in OpenAlex.

What is the ROR of Hebron University?

ScholarIQror

The ROR for Hebron University is on the source record.

What is the OpenAlex record for Hebron University?

ScholarIQopenalex

The OpenAlex for Hebron University is on the source record.

What is the Wikidata of Hebron University?

ScholarIQwikidata

The Wikidata for Hebron University is on the source record.

Who are the most-cited researchers behind Hebron University?

ScholarIQtop researchers by citations
1
Josep Tabernero · Colorectal Cancer Treatments and Studies
2,697 works129,154 citations
2
Enriqueta Felip · Lung Cancer Treatments and Mutations
1,470 works111,423 citations
3
Marc Ribó · Acute Ischemic Stroke Management
778 works44,768 citations
4
Ana Oaknin · Ovarian cancer diagnosis and treatment
720 works37,502 citations
5
Carlos A. Molina · Acute Ischemic Stroke Management
359 works30,800 citations

What are the most-cited papers on Hebron University?

ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
New England Journal of Medicine. 20159,504 CitationsOPEN ACCESS
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
New England Journal of Medicine. 20186,696 CitationsOPEN ACCESS
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
The Lancet. 20156,558 Citations
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
New England Journal of Medicine. 20156,267 CitationsOPEN ACCESS
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares
The Lancet Oncology. 20125,545 CitationsOPEN ACCESS

How much of the research on Hebron University is open access?

ScholarIQopen access share
92%OPEN ACCESS
Gold
0%
Green
25%
Hybrid
8%
Bronze
58%
Closed
8%

Related on ScholarIQ

470M+ articles · 14-day free trial